<p>/PRNewswire/ -- Intensity Therapeutics, Inc.（纳斯达克代码：INTS）是一家处于后期临床阶段的生物技术公司，专注于发现和开发专有的新型免疫基础肿瘤内治疗方法，旨在杀死肿瘤并增强免疫系统对癌症的识别。公司宣布创始人、总裁兼首席执行官 Lewis H. Bender 将在 H.C. Wainwright 第 26 届年度全球投资会议上进行公司概述的演讲。会议将于 2024 年 9 月 9 日至 11 日在纽约乐天酒店举行。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg"/></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>演讲日期：</td>
<td>2024 年 9 月 11 日，星期三</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>时间：</td>
<td>东部时间上午 11:30（Holmes I – 4 楼）</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>网络直播链接：</td>
<td></td>
</tr>
<tr>
<td>https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>演讲的实时网络直播可以在 Intensity Therapeutics 网站的投资者关系部分访问。网络直播的回放将在活动结束后存档，并可在大约 90 天内观看。</p>
<p>https://ir.intensitytherapeutics.com/news-events/events-presentations</p>
<p>Bender 先生和首席财务官 Joseph Talamo 将在整个会议期间提供一对一的会议。要请求会议并注册会议，请点击以下链接：</p>
<p>https://hcwevents.com/annualconference/</p>
<p><strong>关于 Intensity Therapeutics</strong> Intensity Therapeutics 是一家处于后期临床阶段的生物技术公司，应用新型工程化化学，通过使其含水细胞毒药物产品 INT230-6 与肿瘤的高脂肪高压环境混合并饱和。由于饱和，Intensity 的临床试验已证明 INT230-6 能够在注射后几天内杀死肿瘤并引发适应性免疫反应，代表了一种新的癌细胞死亡方法，具有改变治疗范式的潜力，使许多致命癌症转变为慢性疾病，即使是对免疫疗法无反应的癌症。INT230-6 在两项研究中已完成超过 200 名患者的入组；一项是 1/2 期剂量递增试验（NCT03058289），另一项是针对乳腺癌的 2 期随机对照临床试验（INVINCIBLE-2 研究）（NCT04781725）。公司还启动了一项针对软组织肉瘤的 3 期试验（INVINCIBLE-3 研究）（NCT06263231），测试 INT230-6 作为第二或第三线单药治疗，与标准治疗相比，以总体生存率为终点。公司还计划在术前三阴性乳腺癌中进行 2/3 期项目，测试 INT230-6 与标准治疗联合使用，与单独的标准治疗相比。该项目的 2 期部分（INVINCIBLE-4 研究）信息列于（NCT06358573）。有关公司的更多信息，包括关于其新型癌症治疗方法的出版物、论文和海报，请访问 www.intensitytherapeutics.com。</p>
<p><strong>前瞻性声明</strong> 本新闻稿中的某些声明可能构成 1995 年美国私人证券诉讼改革法案（截至目前的修订）所定义的 “前瞻性声明”。这些声明包括但不限于与公司预期未来计划、现金流、开发活动、预计里程碑、商业活动或结果相关的声明。当在本通讯中使用时，诸如 “可能”、“可以”、“应该”、“预期”、“相信”、“估计”、“期望”、“打算”、“计划”、“预测” 等类似表达及其变体，可能识别出前瞻性声明。本新闻稿中包含的前瞻性声明基于管理层对未来事件的当前预期和预测，然而，实际结果或事件可能与披露或暗示的计划、意图和期望有实质性差异。这些风险和不确定性中的许多超出了我们的控制，包括：未来的临床前研究和临床试验及研发项目的启动、时间、进展和结果；在公司预计从产品销售中产生任何收入之前需要筹集额外资金；开发和商业化产品候选者的计划；监管申请和批准的时间或可能性；公司研究生成和推进额外产品候选者的能力；公司商业模式的实施、公司业务、产品候选者和技术的战略计划；商业化、市场营销和制造能力及战略；公司系统的市场接受率和临床效用的速度和程度；公司的竞争地位；公司的知识产权地位；与公司竞争对手及其行业相关的发展和预测；公司维持和建立合作关系或获得额外资金的能力；与现金及现金等价物和投资的使用相关的预期；关于费用、未来收入、资本需求和额外融资需求的估计；以及在公司 SEC 文件中描述的其他风险，相关文件可在 SEC 网站 www.sec.gov 上获取。读者被警告不要对前瞻性声明过于依赖，这些声明仅在作出时有效，并反映管理层的当前估计、预测、期望和信念。公司不计划更新任何此类前瞻性声明，并明确拒绝更新本新闻稿中包含的信息，除非法律要求。</p>
<p><strong>投资者关系联系人：</strong> Justin Kulik</p>
<p>justin@coreir.com</p>
<p>(558) 230-6401</p>
<p><strong>媒体联系人：</strong> Jules Abraham</p>
<p>CORE IR</p>
<p>julesa@coreir.com</p>
<p>来源：Intensity Therapeutics Inc.</p>

INTS

<p>Intensity Therapeutics, Inc.（纳斯达克代码：INTS）将在 2024 年 9 月 11 日的 H.C. Wainwright 第 26 届年度全球投资会议上进行公司概述。首席执行官 Lewis H. Bender 和首席财务官 Joseph Talamo 将会进行一对一的会议。该公司专注于开发基于免疫的癌症疗法，其药物 INT230-6 在多种癌症的临床试验中显示出良好的前景。公告中包含了关于未来计划和风险的前瞻性声明。有关更多详细信息，请访问他们网站的投资者关系部分</p>

<p>, /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Intensity Therapeutics, Inc.（纳斯达克代码：INTS）是一家处于后期临床阶段的生物技术公司，专注于发现和开发专有的新型免疫基础肿瘤内治疗方法，旨在杀死肿瘤并增强免疫系统对癌症的识别。公司宣布创始人、总裁兼首席执行官 Lewis H. Bender 将在 H.C. Wainwright 第 26 届年度全球投资会议上进行公司概述的演讲。会议将于 2024 年 9 月 9 日至 11 日在纽约乐天酒店举行。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg"/></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation Date:</td>
<td>Wednesday, September 11, 2024</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Time:</td>
<td>11:30 AM ET (Holmes I – 4th Floor)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Webcast Link:<br/>https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>演讲日期：</td>
<td>2024 年 9 月 11 日，星期三</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>时间：</td>
<td>东部时间上午 11:30（Holmes I – 4 楼）</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>网络直播链接：</td>
<td></td>
</tr>
<tr>
<td>https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>A live webcast of the presentation can be accessed on the investor relations section of the Intensity Therapeutics website. A replay of the webcast will be archived and available following the event for approximately 90 days.</p>
<div class="lb-trans"><p>演讲的实时网络直播可以在 Intensity Therapeutics 网站的投资者关系部分访问。网络直播的回放将在活动结束后存档，并可在大约 90 天内观看。</p>
</div><p>https://ir.intensitytherapeutics.com/news-events/events-presentations</p>
<div class="lb-trans"><p>https://ir.intensitytherapeutics.com/news-events/events-presentations</p>
</div><p>Mr. Bender and Joseph Talamo, Chief Financial Officer, will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, please click below:</p>
<div class="lb-trans"><p>Bender 先生和首席财务官 Joseph Talamo 将在整个会议期间提供一对一的会议。要请求会议并注册会议，请点击以下链接：</p>
</div><p>https://hcwevents.com/annualconference/</p>
<div class="lb-trans"><p>https://hcwevents.com/annualconference/</p>
</div><p><strong>About Intensity Therapeutics</strong> Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a novel approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for cancers that do not respond to immunotherapy. INT230-6 has completed enrollment of over 200 patients in two studies; a Phase 1/2 dose escalation trial (NCT03058289), and a Phase 2 randomized control clinical trial in breast cancer (the INVINCIBLE-2 study) (NCT04781725). The Company initiated a Phase 3 trial in soft tissue sarcoma (the INVINCIBLE-3 study) (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care with overall survival as an endpoint. The Company is also planning a Phase 2/3 program in presurgical triple negative breast cancer testing INT230-6 in combination with standard of care compared to standard of care alone. Information on the Phase 2 portion of the program (INVINCIBLE-4 Study) is listed under (NCT06358573). For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.</p>
<div class="lb-trans"><p><strong>关于 Intensity Therapeutics</strong> Intensity Therapeutics 是一家处于后期临床阶段的生物技术公司，应用新型工程化化学，通过使其含水细胞毒药物产品 INT230-6 与肿瘤的高脂肪高压环境混合并饱和。由于饱和，Intensity 的临床试验已证明 INT230-6 能够在注射后几天内杀死肿瘤并引发适应性免疫反应，代表了一种新的癌细胞死亡方法，具有改变治疗范式的潜力，使许多致命癌症转变为慢性疾病，即使是对免疫疗法无反应的癌症。INT230-6 在两项研究中已完成超过 200 名患者的入组；一项是 1/2 期剂量递增试验（NCT03058289），另一项是针对乳腺癌的 2 期随机对照临床试验（INVINCIBLE-2 研究）（NCT04781725）。公司还启动了一项针对软组织肉瘤的 3 期试验（INVINCIBLE-3 研究）（NCT06263231），测试 INT230-6 作为第二或第三线单药治疗，与标准治疗相比，以总体生存率为终点。公司还计划在术前三阴性乳腺癌中进行 2/3 期项目，测试 INT230-6 与标准治疗联合使用，与单独的标准治疗相比。该项目的 2 期部分（INVINCIBLE-4 研究）信息列于（NCT06358573）。有关公司的更多信息，包括关于其新型癌症治疗方法的出版物、论文和海报，请访问 www.intensitytherapeutics.com。</p>
</div><p><strong>Forward-Looking Statements</strong> Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;predict&#34; and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled &#34;Risk Factors&#34; in the Company's SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.</p>
<div class="lb-trans"><p><strong>前瞻性声明</strong> 本新闻稿中的某些声明可能构成 1995 年美国私人证券诉讼改革法案（截至目前的修订）所定义的 “前瞻性声明”。这些声明包括但不限于与公司预期未来计划、现金流、开发活动、预计里程碑、商业活动或结果相关的声明。当在本通讯中使用时，诸如 “可能”、“可以”、“应该”、“预期”、“相信”、“估计”、“期望”、“打算”、“计划”、“预测” 等类似表达及其变体，可能识别出前瞻性声明。本新闻稿中包含的前瞻性声明基于管理层对未来事件的当前预期和预测，然而，实际结果或事件可能与披露或暗示的计划、意图和期望有实质性差异。这些风险和不确定性中的许多超出了我们的控制，包括：未来的临床前研究和临床试验及研发项目的启动、时间、进展和结果；在公司预计从产品销售中产生任何收入之前需要筹集额外资金；开发和商业化产品候选者的计划；监管申请和批准的时间或可能性；公司研究生成和推进额外产品候选者的能力；公司商业模式的实施、公司业务、产品候选者和技术的战略计划；商业化、市场营销和制造能力及战略；公司系统的市场接受率和临床效用的速度和程度；公司的竞争地位；公司的知识产权地位；与公司竞争对手及其行业相关的发展和预测；公司维持和建立合作关系或获得额外资金的能力；与现金及现金等价物和投资的使用相关的预期；关于费用、未来收入、资本需求和额外融资需求的估计；以及在公司 SEC 文件中描述的其他风险，相关文件可在 SEC 网站 www.sec.gov 上获取。读者被警告不要对前瞻性声明过于依赖，这些声明仅在作出时有效，并反映管理层的当前估计、预测、期望和信念。公司不计划更新任何此类前瞻性声明，并明确拒绝更新本新闻稿中包含的信息，除非法律要求。</p>
</div><p><strong>Investor Relations Contact:</strong> Justin Kulik</p>
<div class="lb-trans"><p><strong>投资者关系联系人：</strong> Justin Kulik</p>
</div><p>justin@coreir.com</p>
<div class="lb-trans"><p>justin@coreir.com</p>
</div><p>(558) 230-6401</p>
<div class="lb-trans"><p>(558) 230-6401</p>
</div><p><strong>Media Contact:</strong> Jules Abraham</p>
<div class="lb-trans"><p><strong>媒体联系人：</strong> Jules Abraham</p>
</div><p>CORE IR</p>
<div class="lb-trans"><p>CORE IR</p>
</div><p>julesa@coreir.com</p>
<div class="lb-trans"><p>julesa@coreir.com</p>
</div><p>SOURCE Intensity Therapeutics Inc.</p>
<div class="lb-trans"><p>来源：Intensity Therapeutics Inc.</p>
</div>

Saia 宣布品牌整合 | SAIA 股票新闻